Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Arhaus Reports Surprising Quarterly Earnings Beat

Elaine Mendonca by Elaine Mendonca
March 7, 2024
in Breaking News
0
DrugRetailers Trading online
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

Arhaus (NASDAQ: ARHS) surprised investors with their latest quarterly report on March 7, 2024. The company announced adjusted earnings of $0.22 per share, beating the analyst consensus by 37.5%. This is a slight decrease of 35.29% from the previous year’s earnings of $0.34 per share.

In addition, Arhaus reported quarterly sales of $344.01 million, surpassing the analyst estimate by 2.83%. However, this represents a 3.46% decrease from sales in the same period last year, totaling $356.33 million.

Investors are eagerly awaiting the upcoming financial results for Arhaus, with analysts predicting a decline in both revenue and adjusted earnings for the quarter.

ARHS Stock Shows Signs of Recovery with Pre-Market Rise

On March 7, 2024, ARHS stock exhibited mixed performances as it traded near the top of its 52-week range and above its 200-day simple moving average. According to data from CNN Money, the price of ARHS shares experienced a slight decrease of $0.11 since the market last closed, representing a 0.85% drop from its previous closing price of $12.82.

Despite this slight decline, ARHS stock showed signs of potential recovery as it rose by $0.18 in pre-market trading. This upward movement in the pre-market session could indicate a shift in investor sentiment towards the stock, potentially leading to a positive trading day ahead.

ARHS Stock Analysis: Strong Growth in Revenue and Net Income, Mixed Performance in Third Quarter

On March 7, 2024, ARHS stock experienced mixed performances based on the financial data provided by CNN Money. The company’s total revenue for the past year was reported at $1.23 billion, which represents a significant increase of 54.21% compared to the previous year. Additionally, the total revenue for the third quarter of the fiscal year stood at $326.23 million, showing a 4.26% increase from the previous quarter.

In terms of net income, ARHS reported a net income of $136.63 million for the past year, reflecting a substantial growth of 547.03% compared to the previous year. However, the net income for the third quarter was reported at $19.74 million, indicating a decrease of 50.87% from the previous quarter.

Earnings per share (EPS) also showed a mixed performance for ARHS stock. The EPS for the past year was reported at $0.98, representing a significant increase of 534.7% compared to the previous year. However, the EPS for the third quarter was reported at $0.14, showing a decrease of 50.92% from the previous quarter.

Overall, ARHS stock demonstrated strong growth in total revenue and net income over the past year, indicating positive financial performance. However, the decrease in net income and EPS for the third quarter may have raised concerns among investors. It is important for investors to closely monitor the company’s financial performance and future outlook to make informed investment decisions.

Tags: ARHS
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Retail Stock Bull Market

Arhaus Projects Strong Financial Performance for 2024

CRWD stock news

Entegris NASDAQ ENTG Receives Buy Recommendation and 150 Price Target from Needham Analyst

Retail Stock Bull Market

BJs Wholesale Club Exceeds Earnings Expectations in Q1 2024

Recommended

UBS Stock

UBS Share Buyback Fails to Impress Amid Regulatory Fears

3 months ago
IBM Stock

IBM’s UFC Partnership Showcases AI Capabilities in Live Sports

3 months ago
ImmunityBio Stock

ImmunityBio Shares Gain Momentum on Strong Revenue and Regulatory Progress

6 days ago
BioNTech Stock

BioNTech’s Billion-Euro Forecast Shift Stuns Market

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Trending

Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

by Jackson Burston
February 8, 2026
0

Investors in Rock Tech Lithium are in a holding pattern, with all eyes fixed on a pending...

Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rock Tech Lithium: Investors Await the Final Go-Ahead
  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com